Compare F5 Inc (FFIV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs TG Therapeutics Inc — how do they compare? F5 Inc trades at $480.54 (market cap $26.14B), while TG Therapeutics Inc trades at $54.8 (market cap $8.16B). The key difference: F5 Inc is far larger — about 3.2× TG Therapeutics Inc's market cap, and F5 Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and TG Therapeutics Inc for 16 Days on average.
| FFIV | TGTX | |
|---|---|---|
Market Cap | $26.14B | $8.16B |
Volume | 503,146 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $469.79 | $59.06 |
52-Week Low | $223.99 | $26.94 |
Typical Hold Time | 38 Days | 16 Days |
Enterprise Value | $24.78B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $479.27, up 2.7% on the day and near its 52-week high, with a bullish technical trend and strong support at $457. The company reported robust earnings, beating estimates for three consecutive quarters, with Q3 2026 EPS expected at $4.26. Revenue growth accelerated to $3.09B in 2025, and net income margin improved to 22.42%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook for FFIV is positive, driven by earnings momentum and strategic positioning in AI security. However, the stock's elevated valuation multiples (P/E of 36.78) pose a risk if growth slows. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite bullish technicals. Key risks include competitive pressures and execution challenges in integrating new technologies.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
